membranous nephropathy
Conditions
Interventions
Grouping according to different treatment plans:None
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Primary MN confirmed by renal biopsy; 18-80 years old; 2.eGFR > 30ml/min/1.73m2; 3.fully understood this study and voluntarily signed the informed consent;
Exclusion criteria
Exclusion criteria: 1.Secondary MN, such as systemic autoimmune diseases, solid tumors or hematological malignancies, infections, or long-term ingestion of drugs (e.g., gold salts, NSAID, penicillamine); 2.Concomitant with other glomerular diseases, such as diabetic nephropathy, renal significance monoclonal immunoglobulin syndrome (MGRS), small vasculitis renal damage, anti-glomerular basement membrane nephritis, IgA nephropathy, micropathological nephropathy, focal segmental glomerulosclerosis, etc; 3.Malignant tumors (other than local basal cell carcinoma of the skin or cervical cancer in situ) within 5 years, regardless of treatment and with or without signs of local recurrence or metastasis; 4.Hepatitis B surface antigen (HBsAg) or HBV-DNA exceeds the normal range; Hepatitis C virus (HCV) antibody positive; Human immunodeficiency virus (HIV) seropositive; 5.Participate in other clinical trials currently or within the last month; 6.Severe other poorly controlled diseases, including cardiovascular and cerebrovascular diseases requiring hospitalization, cirrhosis, etc., with a life expectancy of < 1 year; 7.Compliance with the study protocol was considered difficult by the treating physician;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary protein;serum creatinine;serum albumin; | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum anti- PLA2R antibody; | — |
Countries
China
Contacts
Public ContactMinghui Zhao
Peking University First Hospital
Outcome results
None listed